Baird's Investment Banking Group is pleased to announce the following transaction:

August 2021
Sale to WCG
Baird served as the exclusive financial advisor to VeraSci on this transaction

VeraSci was recently acquired by WCG. Terms of the transaction were not disclosed.

Founded in 2004, VeraSci provides clients around the world with innovative solutions that improve data quality in clinical trials, including endpoint and assessment services, rater training and certification, language and translation support, and eCOA and ePRO technologies. With its Pathway technology platform, which can be easily configured to meet the needs of any study across the globe, VeraSci enables the collection of high-quality data that can be used to assess symptoms, cognition and functional capacity in a wide range of therapeutic indications. VeraSci is based in Durham, North Carolina.

WCG is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two segments, Ethical Review and Clinical Trials Solutions (CTS), WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection. WCG is headquartered in Princeton, New Jersey.

For additional information about this transaction, please contact:

Bill Suddath +1-312-609-5441
Miguel Mireles +1-414-298-2478
Adam Huitt +1-704-553-6623
Andrew Nicholson +44-20-7667-8509